离子钙与隐藏性低钙血症对透析患者心血管结局的临床影响
基于前瞻性多中心ORCHESTRA队列637例维持性透析患者,分析基线及6、12个月离子钙水平与心血管结局的关联。中位随访1.1年发生61例MACE和52例死亡。总钙及白蛋白校正钙分类与MACE或死亡无显著关联,但≥2次离子钙低值及隐藏性低钙血症与MACE风险升高相关,未发现钙类别与死亡的关联。
要点
- 总钙及校正钙分类与MACE或全因死亡无显著关联
- ≥2次离子钙低值者MACE风险升高(校正HR 3.62)
- 隐藏性低钙血症与MACE风险升高相关,需关注钙检测不一致
核心结论
- 总钙和白蛋白校正钙与心血管结局无关联,而反复隐藏性低钙血症与MACE风险升高相关。
- 评估总钙与离子钙之间的不一致可能提供超越常规钙指标的临床相关信息。
研究设计与样本
- 前瞻性多中心ORCHESTRA队列研究,纳入637例维持性透析患者,基线及6、12个月测量离子钙。
- 为减少反向因果,排除前12个月内发生事件的患者后进行时间-事件分析。
- 采用Cox模型评估基线及纵向钙分类与MACE(心血管死亡、非致死性心肌梗死或非致死性卒中)及全因死亡的关联。
主要发现
- 12个月评估后中位随访1.1年,发生61例MACE和52例死亡。
- 采用12个月平均值评估时,总钙、校正钙及离子钙分类与MACE或死亡均无显著关联。
- ≥2次离子钙低值测量者MACE风险升高(校正HR 3.62;95%CI 1.25-10.46)。
- 隐藏性低钙血症(总钙或校正钙正常而离子钙低)与MACE风险升高相关:基线总钙×离子钙HR 2.94,校正钙×离子钙HR 2.81;纵向校正钙×离子钙≥2次HR 4.58。
- 任何钙类别均与死亡无关联。
临床怎么用
- 透析患者心血管风险评估中可考虑监测离子钙,识别总钙正常但离子钙低的隐藏性低钙血症。
- 反复离子钙低值或隐藏性低钙血症患者可能需加强心血管风险关注。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Calcium homeostasis is critical for cardiovascular health in chronic kidney disease (CKD). Ionized calcium is biologically active, but clinical monitoring typically relies on total or albumin-corrected calcium, which may misclassify calcium status and mask abnormalities such as hidden hypocalcemia. We examined the associations of ionized calcium levels and hidden hypocalcemia with cardiovascular outcomes in dialysis patients. METHODS: We analyzed 637 maintenance dialysis patients from the prospective, multicenter ORCHESTRA cohort with ionized calcium measurements at baseline, 6, and 12 months. To minimize reverse causality, patients experiencing events within the first 12 months were excluded from time-to-event analyses. Total, albumin-corrected, and ionized calcium were categorized as low, normal, or high, and patients were further classified into concordant or discordant groups (both normal, hidden hypocalcemia, true hypocalcemia, hidden hypercalcemia, true hypercalcemia). Cox models assessed associations of baseline and longitudinal calcium categories with major adverse cardiovascular events (MACE; cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) and all-cause mortality. RESULTS: During a median follow-up of 1.1 years after the 12-month assessment, 61 MACE and 52 deaths occurred. When evaluated using 12-month averaged values, total, corrected, and ionized calcium categories were not significantly associated with MACE or mortality. However, patients with ≥2 ionized hypocalcemic measurements had a higher risk of MACE (adjusted hazard ratio (HR) 3.62; 95% confidence intervals 1.25-10.46). Hidden hypocalcemia (normal total or corrected calcium with low ionized calcium) was associated with increased MACE risk both at baseline (total × ionized HR 2.94; corrected × ionized HR 2.81) and in longitudinal analyses (corrected × ionized ≥ 2 episodes HR 4.58). No calcium category was associated with mortality. CONCLUSIONS: Total and albumin-corrected calcium were not associated with cardiovascular outcomes. By contrast, recurrent hidden hypocalcemia was associated with excess MACE risk. These findings suggest that evaluating discordance between total and ionized calcium may provide clinically relevant information beyond conventional calcium measures in dialysis patients.
引用
- Kim JE, Kang D, Song SM, et al. Clinical impact of ionized calcium and hidden hypocalcemia on cardiovascular outcomes in dialysis patients. Nephrol Dial Transplant. 2026. PMID: 41823312. doi:10.1093/ndt/gfag057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。